Value of top 10 yet to close pharmaceutical deals Q1 2017

Top 10 yet-to-close pharmaceutical deals worldwide based on value announced in the first quarter of 2017 (in billion U.S. dollars)*

Value of top 10 yet to close pharmaceutical deals Q1 2017 This statistic displays the top 10 yet to close pharmaceutical deals worldwide based on value announced in the first quarter of 2017. Johnson & Johnson has bid a deal for Actelion valued at 30 billion U.S. dollars.
Show more

Top 10 yet-to-close pharmaceutical deals worldwide based on value announced in the first quarter of 2017 (in billion U.S. dollars)*

Loading statistic...
Bidder (Target)Value in billion U.S. dollars
Johnson & Johnson (Actelion)30
Cinven Partners LLP and Bain Capital Lp (STADA Arzneimittel AG)5.6
Ipsen S.A. (Merrimack Pharmaceuticals Inc.- oncology assets)1
Creat Group Corp. (Biotest AG)1
Sanpower Group Co. Ltd (Valeant Pharmaceuticals International Inc.-oncology assets)0.8
Celgene Corp. (Delinia Inc.)0.8
Investor group including Giant Star Global Ltd. and Lucky Ltd. (Shandong Luoxin Pharmaceutical Group Co., Ltd)0.3
Liu Xicheng (Hainan Haiyao Co. Ltd 10%)0.3
Otsuka (Neurovance)0.3
Generex Biotechnology Corp. (Emmaus Medical Inc. 51%)0.2
Bidder (Target)Value in billion U.S. dollars
Johnson & Johnson (Actelion)30
Cinven Partners LLP and Bain Capital Lp (STADA Arzneimittel AG)5.6
Ipsen S.A. (Merrimack Pharmaceuticals Inc.- oncology assets)1
Creat Group Corp. (Biotest AG)1
Sanpower Group Co. Ltd (Valeant Pharmaceuticals International Inc.-oncology assets)0.8
Celgene Corp. (Delinia Inc.)0.8
Investor group including Giant Star Global Ltd. and Lucky Ltd. (Shandong Luoxin Pharmaceutical Group Co., Ltd)0.3
Liu Xicheng (Hainan Haiyao Co. Ltd 10%)0.3
Otsuka (Neurovance)0.3
Generex Biotechnology Corp. (Emmaus Medical Inc. 51%)0.2
Download Settings Share
Download started
Please be patient - this may take a moment
This statistic displays the top 10 yet to close pharmaceutical deals worldwide based on value announced in the first quarter of 2017. Johnson & Johnson has bid a deal for Actelion valued at 30 billion U.S. dollars.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.